nach oben

Current Reviews in Musculoskeletal Medicine

Erschienen in:

28.05.2020 | Stem Cells in Orthopaedic Surgery (J Dragoo and KJ Jones, Section Editors)

Ethical and Practical Considerations for Integrating Cellular (“Stem Cell”) Therapy into Clinical Practice

verfasst von: Nicolas S. Piuzzi, Ahmed Emara, Jorge Chahla, Bert R. Mandelbaum

Erschienen in: Current Reviews in Musculoskeletal Medicine | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cellular therapies, also known as “stem cell” interventions (SCI), have undergone a rapid popularization in the USA and worldwide. The current review aimed at outlining (1) the ethical challenges facing the implementation of SCI; (2) the applicability of the currently available SCI; and (3) recommendations to achieve ethical, well-regulated incorporation of SCI in the clinical setting.

Recent Findings

Concerns regarding the inadequate characterization, poor adverse effects disclosure, and unorthodox, often inappropriate, market practices have engendered a genuine concern regarding the SCI compliance with ethical standards. Six instances of litigation on the basis of misrepresentation or inappropriate informed consent were recorded between 2012 and 2018. Such concerns have been furthered by the loopholes in the regulatory aspect governing the use of SCI coupled with the unclear literature-reported efficacy and diverse spectrum of profess indications. Similarly, the application of SCI in the clinical field is yet to prove its value. The uncertain efficacy, coupled with obscure true-costs of utilization, impedes a value-based assessment.

Summary

A multidisciplinary approach involving legislative and medical professional societies should continue to advance regulations that govern SCI. A well-regulated system that allows for the ethical integration of SCI with appositely evidenced-based described benefits and risks should be sought.

Bauer TW. Stem cell therapy for knee pain—what exactly are we injecting, and why? J Bone Jt Surg. 2016;98(18):1509–10. https://doi.org/10.2106/JBJS.16.00872.CrossRef

Piuzzi NS, Ng M, Chughtai M, Khlopas A, Ng K, Mont M, et al. The stem-cell market for the treatment of knee osteoarthritis: a patient perspective. J Knee Surg. 2018;31(6):551–6. https://doi.org/10.1055/s-0037-1604443.CrossRefPubMed

• Ng M, Song S, Piuzzi NS, et al. Stem cell industry update: 2012 to 2016 reveals accelerated investment, but market capitalization and earnings lag. Cytotherapy. 2017;19(10):1131–9. https://doi.org/10.1016/j.jcyt.2017.07.006Outlines the rising trends within the stem cell market.

Nho SJ, Kymes SM, Callaghan JJ, Felson DT. The burden of hip osteoarthritis in the United States: epidemiologic and economic considerations. J Am Acad Orthop Surg. 2013;21(suppl):S1–6. https://doi.org/10.5435/JAAOS-21-07-S1.CrossRefPubMed

Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15(8 Suppl):S230–5.PubMed

Maumus M, Guérit D, Toupet K, Jorgensen C, Noël D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther. 2011;2(2):1–6. https://doi.org/10.1186/scrt55.CrossRef

Syed BA, Evans JB. Stem cell therapy market. Nat Rev Drug Discov. 2013;12(3):185–6. https://doi.org/10.1038/nrd3953.CrossRefPubMed

• Ng MK, Mont MA, Piuzzi NS. Analysis of readability, quality, and content of online information available for “stem cell” injections for knee osteoarthritis. J Arthroplasty. 2020;35(3):647–651.e2. https://doi.org/10.1016/j.arth.2019.10.013Highlights the poor characterization of the marketed stem cell interventions on digital platforms. CrossRefPubMed

Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2017;51(15):1125–33. https://doi.org/10.1136/bjsports-2016-096793.CrossRefPubMed

10.

Jevotovsky DS, Alfonso AR, Einhorn TA, Chiu ES. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthr Cartil. 2018;26(6):711–29. https://doi.org/10.1016/j.joca.2018.02.906.CrossRefPubMed

11.

Papakostidis C, Tosounidis TH, Jones E, Giannoudis PV. The role of “cell therapy” in osteonecrosis of the femoral head. Acta Orthop. 2016;87(1):72–8. https://doi.org/10.3109/17453674.2015.1077418.CrossRefPubMed

12.

Chahla J, Piuzzi NS, Mitchell JJ, Dean CS, Pascual-Garrido C, LaPrade RF, et al. Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee: a systematic review of the literature and study quality analysis. J Bone Jt Surg - Am. 2016;98(18):1511–21. https://doi.org/10.2106/JBJS.15.01495.CrossRef

13.

Murray IR, Chahla J, Frank RM, Piuzzi NS, Mandelbaum BR, Dragoo JL, et al. Rogue stem cell clinics. Bone Joint J. 2020;102-B(2):148–54. https://doi.org/10.1302/0301-620X.102B2.BJJ-2019-1104.R1.CrossRefPubMedPubMedCentral

14.

•• Piuzzi NS, Dominici M, Long M, et al. Proceedings of the signature series symposium “cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy,” international society for cellular therapies, montreal, canada, may 2, 2018. Cytotherapy. 2018;20(11):1381–400. https://doi.org/10.1016/j.jcyt.2018.09.001Provides guidelines and recommendations that aid in the identification of proven vs. unproven stem cell therapies.CrossRefPubMed

15.

•• Chu CR, Rodeo S, Bhutani N, et al. Optimizing clinical use of biologics in orthopaedic surgery: consensus recommendations from the 2018 AAOS/NIH U-13 conference. J Am Acad Orthop Surg. 2019;27(2):e50–63. https://doi.org/10.5435/JAAOS-D-18-00305Provides guidelines elucidating the proper use designation of stem cell therapies in orthopaedics. CrossRefPubMed

16.

Ellison B. Stem cell research and social justice : aligning scientific progress with social need. Curr Stem Cell Reports. 2016;2:328–35. https://doi.org/10.1007/s40778-016-0063-3.CrossRef

17.

Nherera LM, Trueman P, Horner A, Johnstone AJ, Watson TJ, Fatoye FA. Comparing the costs and outcomes of an integrated twin compression screw (ITCS) nail with standard of care using a single lag screw or a single helical blade cephalomedullary nail in patients with intertrochanteric hip fractures. J Orthop Surg Res. 2018;13(1):1–8. https://doi.org/10.1186/s13018-018-0923-x.CrossRef

18.

•• Murray IR, Chahla J, Frank RM, Piuzzi NS, Mandelbaum BR, Dragoo JL. Rogue stem cell clinics. Bone Joint J. 2020;102-B(2):148–54. https://doi.org/10.1302/0301-620X.102B2.BJJ-2019-1104.R1Outlines the magnitude of the direct-to-consumer marketing practices and provides recommendations for sufficient regulation.CrossRefPubMedPubMedCentral

19.

Frow EK, Brafman DA, Muldoon A, Krum L, Williams P, Becker B, et al. Characterizing direct-to-consumer stem cell businesses in the Southwest United States. Stem Cell Reports. 2019;13(2):247–53. https://doi.org/10.1016/j.stemcr.2019.07.001.CrossRefPubMedPubMedCentral

20.

Piuzzi NS, Chahla J, Jiandong H, Chughtai M, LaPrade RF, Mont MA, et al. Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplast. 2017;32(8):2612–8. https://doi.org/10.1016/j.arth.2017.02.075.CrossRef

21.

Marcucio RS, Nauth A, Giannoudis PV, Bahney C, Piuzzi NS, Muschler G, et al. Stem cell therapies in orthopaedic trauma. J Orthop Trauma. 2015;29(Suppl 12):S24–7. https://doi.org/10.1097/BOT.0000000000000459.CrossRefPubMedPubMedCentral

22.

Vakharia RM, Roche MW, Alcerro JC, Lavernia CJ. The current status of cell- based therapies for primary knee osteoarthritis. Orthop Clin NA. 2019;50(4):415–23. https://doi.org/10.1016/j.ocl.2019.06.001.CrossRef

23.

Shakouri-Motlagh A, Khanabdali R, Heath DE, Kalionis B. The application of decellularized human term fetal membranes in tissue engineering and regenerative medicine (TERM). Placenta. 2017;59:124–30. https://doi.org/10.1016/j.placenta.2017.07.002.CrossRefPubMed

24.

Pogozhykh O, Prokopyuk V, Figueiredo C, Pogozhykh D. Review article placenta and placental derivatives in regenerative therapies : experimental studies. Hist Prospects. 2018;2018.

25.

Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254–66. https://doi.org/10.1002/stem.1634.CrossRefPubMed

26.

Wyles CC, Houdek MT, Behfar A, Sierra RJ. Mesenchymal stem cell therapy for osteoarthritis: current perspectives. Stem Cells Cloning Adv Appl. 2015;8:117–24. https://doi.org/10.2147/SCCAA.S68073.CrossRef

27.

Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. 2012;19(6):902–7. https://doi.org/10.1016/j.knee.2012.04.001.CrossRefPubMed

28.

Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2016;14(1):1–9. https://doi.org/10.1186/s12967-016-0998-2.CrossRef

29.

Hurley ET, Yasui Y, Gianakos AL, Seow D, Shimozono Y, Kerkhoffs GMMJ, et al. Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis. Knee Surgery, Sport Traumatol Arthrosc. 2018;26(11):3499–507. https://doi.org/10.1007/s00167-018-4955-x.CrossRef

30.

Peeters CMM, Leijs MJC, Reijman M, van Osch GJVM, Bos PK. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthr Cartil. 2013;21(10):1465–73. https://doi.org/10.1016/j.joca.2013.06.025.CrossRefPubMed

31.

Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23. https://doi.org/10.1136/ard.2008.092015.CrossRefPubMed

32.

Zhang W. The powerful placebo effect in osteoarthritis. Clin Exp Rheumatol. 2019;37(5):118–23.PubMed

33.

Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018;7(9):676–85. https://doi.org/10.1002/sctm.17-0282.CrossRefPubMedPubMedCentral

34.

Turner L. The US Direct-to-consumer marketplace for autologous stem cell interventions. Perspect Biol Med. 2018;61(1):7–24. https://doi.org/10.1353/pbm.2018.0024.CrossRefPubMed

35.

Knoepfler PS. The stem cell hard sell: report from a clinic’s patient recruitment seminar. Stem Cells Transl Med. 2017;6(1):14–6. https://doi.org/10.5966/sctm.2016-0208.CrossRefPubMed

36.

Caulfield T, Sipp D, Murry CE, Daley GQ, Kimmelman J, SCIENTIFIC COMMUNITY. Confronting stem cell hype. Science. 2016;352(6287):776–7. https://doi.org/10.1126/science.aaf4620.CrossRefPubMed

37.

Im G-I. Clinical use of stem cells in orthopaedics. Eur Cell Mater. 2017;33:183–96. https://doi.org/10.22203/eCM.v033a14.CrossRefPubMed

38.

Palsis JA, Brehmer TS, Pellegrini VD, Drew JM, Sachs BL. The cost of joint replacement: comparing two approaches to evaluating costs of total hip and knee arthroplasty. J Bone Joint Surg Am. 2018;100(4):326–33. https://doi.org/10.2106/JBJS.17.00161.CrossRefPubMed

39.

Piuzzi NS, Mantripragada VP, Sumski A, Selvam S, Boehm C, Muschler GF. Bone marrow-derived cellular therapies in orthopaedics: part I: recommendations for bone marrow aspiration technique and safety. JBJS Rev. 2018;6(11):e4. https://doi.org/10.2106/JBJS.RVW.18.00007.CrossRefPubMed

40.

Horner C, Tenenbaum E, Sipp D, Master Z. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions. NPJ Regen Med. 2018;3(1):1–4. https://doi.org/10.1038/s41536-018-0043-6.CrossRef

41.

Turner L. Direct-to-consumer marketing of stem cell interventions by Canadian businesses. Regen Med. 2018;13(6):643–58. https://doi.org/10.2217/rme-2018-0033.CrossRefPubMed

42.

Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019;15(2):77–90. https://doi.org/10.1038/s41584-018-0123-4.CrossRefPubMedPubMedCentral

43.

Sipp D. The malignant niche: safe spaces for toxic stem cell marketing. NPJ Regen Med. 2017;2(1). https://doi.org/10.1038/s41536-017-0036-x.

44.

Browne JA, Nho SJ, Goodman SB, Della Valle CJ. American association of hip and knee surgeons, hip society, and knee society position statement on biologics for advanced hip and knee arthritis. J Arthroplast. 2019;34(6):1051–2. https://doi.org/10.1016/j.arth.2019.03.068.CrossRef

Titel: Ethical and Practical Considerations for Integrating Cellular (“Stem Cell”) Therapy into Clinical Practice
verfasst von: Nicolas S. Piuzzi
Ahmed Emara
Jorge Chahla
Bert R. Mandelbaum
Publikationsdatum: 28.05.2020
Verlag: Springer US
Erschienen in: Current Reviews in Musculoskeletal Medicine / Ausgabe 4/2020
Elektronische ISSN: 1935-9748
DOI: https://doi.org/10.1007/s12178-020-09647-7

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Ethical and Practical Considerations for Integrating Cellular (“Stem Cell”) Therapy into Clinical Practice